• 28.10.2019 – 19:00

  Merck KGaA

  European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

  Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen ...

  more

• 09.10.2019 – 08:00

  Debiopharm International SA

  A pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor-resistant disease by combining IAP antagonist Debio 1143 with Keytruda®

  Lausanne (ots) - First patient enrolled in the investigator initiated CATRIPCA study (Combination with an IAP Antagonist To Reverse Immune resistance in Pancreatic and Colorectal Adenocarcinoma) at the Léon Bérard Cancer Center in Lyon France Debiopharm (www.debiopharm.com) announced today the first patient ...

  more

• 30.09.2019 – 10:00

  Debiopharm International SA

  Debiopharm's novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients

  Lausanne (ots) - Late breaking abstract results presented today at ESMO with chemo-radio sensitizer Debio 1143 present a promising breakthrough strategy to improve the front-line treatment of H&N cancer patients Debiopharm, a Swiss-based global biopharmaceutical company, presented today, at the ESMO Congress ...

  more

• 27.09.2019 – 12:00

  Sysmex Inostics GmbH

  Sysmex Inostics launches two NGS-based liquid biopsy panels for cancer therapy drug development

  Hamburg, Germany and Baltimore, Maryland (ots) - Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. SafeSEQ is a next-generation sequencing (NGS)-based approach that delivers sensitivity comparable to the clinically ...

  more

• 23.09.2019 – 08:01

  Merck KGaA

  New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care

  Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: ...

  more

• 20.09.2019 – 14:10

  Merck KGaA

  CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

  Darmstadt, Germany and New York, Us (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission ...

  more

• 09.09.2019 – 09:00

  Norgine

  SpePharm AG Wins Case Against Eisai Inc. in United States District Court for District of Delaware

  Amsterdam (ots/PRNewswire) - SpePharm AG, a subsidiary of Norgine B.V., announced that the United States District Court for the District of Delaware ruled on 4th September 2019 in favour of SpePharm in its proceeding against Eisai Inc., upholding SpePharm's licensed rights for SALAGEN® (pilocarpine hydrochloride) ...

  more

• 03.09.2019 – 09:00

  Debiopharm International SA

  Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients

  Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced positive topline results across clinical endpoints following the completion of the two-year follow-up period of its double-blind, randomized Phase II study of Debio 1143 in high-risk, previously untreated ...

  more

• 21.05.2019 – 09:00

  Debiopharm International SA

  Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

  Lausanne, Switzerland (ots) - First patient enrolled in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors Debiopharm (www.debiopharm.com) announced today the first patient enrolled in SMARTPLUS-106, an exploratory study investigating the safety and efficacy of ...

  more

• 19.03.2019 – 23:47

  Merck KGaA

  Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...

  more

• 16.02.2019 – 23:10

  Merck KGaA

  Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...

  more

• 11.02.2019 – 23:55

  Merck KGaA

  FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...

  more

• 21.12.2018 – 20:02

  Merck KGaA

  Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...

  more

• 19.11.2018 – 13:08

  Merck KGaA

  Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared ...

  more

• 09.10.2018 – 08:01

  Merck KGaA

  Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care

  Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF β-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: ...

  more

• 11.09.2018 – 14:31

  Merck KGaA

  BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...

  more